Management of Common Side Effects of Apremilast. - Wikidata - awgldk - TriplyDB

Management of Common Side Effects of Apremilast.

Management of Common Side Effects of Apremilast.

http://www.wikidata.org/entity/Q49382144

about

Management of Common Side Effects of Apremilast.

http://www.wikidata.org/entity/Q49382144

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Management of Common Side Effects of Apremilast.

@en

Management of Common Side Effects of Apremilast.

@nl

type

label

Management of Common Side Effects of Apremilast.

@en

Management of Common Side Effects of Apremilast.

@nl

prefLabel

Management of Common Side Effects of Apremilast.

@en

Management of Common Side Effects of Apremilast.

@nl

P1433

Q49382144-CB32254C-FB29-45BD-97D1-FB261CA30FCC

P1476

Q49382144-78297C2B-87E3-4C3B-9536-F4BA8D9C029B

P2093

Q49382144-904E6DD2-C67A-4D57-B85F-5D835D789C7E

Q49382144-9A125E80-9AFA-439A-9EE7-FE07B0471642

P2860

Q49382144-03E9BDAF-8F44-450D-A6CC-748742B3D543

Q49382144-0A9FDD70-F5D9-4291-BE32-9FD8AC9041FC

Q49382144-1639E43A-A5FC-4EC0-9210-FEF63929B9C7

Q49382144-19E901B1-75C1-4F1D-80AD-2D9DC9040012

Q49382144-2A3E1083-CCD3-4C07-A8EA-CFA8A35CB0EB

Q49382144-35609976-8627-4D3F-813A-797EE0904095

Q49382144-39492C3E-948B-4E1E-B295-00E44FF7DD7C

Q49382144-3A6BF059-D612-4616-B977-82C702E67406

Q49382144-46C3D503-BE23-400B-93CE-0E42D8F0AD87

Q49382144-65B2E2C5-D343-48D0-8AE3-7A8F0166CA13

P304

Q49382144-F6BD7864-D588-4EDA-A12B-D0DE5D1C878E

P31

Q49382144-50b71550-06d8-4153-a810-14ee618d65c4

Q49382144-B71288F7-E1B8-414D-BCFE-C224FFF27879

P356

Q49382144-94F109C6-9724-44F6-817C-767BF4A29AE1

P577

Q49382144-17562729-31C4-4B8C-A931-D6EDD7AB2A47

P698

Q49382144-72CE86EA-C4AE-48AA-BA77-AF0EF18904AE

P356

1203475417748886

P1433

Journal of cutaneous medicine and surgery

P1476

Management of Common Side Effects of Apremilast.

@en

P2093

Annie Langley

http://www.w3.org/2001/XMLSchema#string

Jennifer Beecker

http://www.w3.org/2001/XMLSchema#string

P2860

Practice guidelines for the management of infectious diarrhea.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.

Drug-induced diarrhoea.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Drug-induced diarrhea.

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

Apremilast: first global approval.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

P304

1203475417748886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1203475417748886

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29290125

http://www.w3.org/2001/XMLSchema#string